The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Paul O'Connor

St. Michael's Hospital

30 Bond St.

Suite 3-007 Shuter Wing

Toronto

[email]@smh.toronto.on.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • St. Michael's Hospital, 30 Bond St., Suite 3-007 Shuter Wing, Toronto. 2002 - 2011
  • St Michael's Hospital, Toronto, Canada. 2004 - 2009
  • University of Toronto, Ontario, Canada. 2006

References

  1. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. O'Connor, P.W., Goodman, A., Kappos, L., Lublin, F.D., Miller, D.H., Polman, C., Rudick, R.A., Aschenbach, W., Lucas, N. Neurology (2011) [Pubmed]
  2. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.P., Jeffery, D., Kappos, L., Boateng, F., Filippov, V., Groth, M., Knappertz, V., Kraus, C., Sandbrink, R., Pohl, C., Bogumil, T., O'Connor, P., Filippi, M., Arnason, B., Cook, S., Goodin, D., Harung, H.P., Kappos, L., Jeffery, D., Comi, G. Lancet. Neurol (2009) [Pubmed]
  3. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. O'Connor, P., Comi, G., Montalban, X., Antel, J., Radue, E.W., de Vera, A., Pohlmann, H., Kappos, L. Neurology (2009) [Pubmed]
  4. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. O'Connor, P., Kinkel, R.P., Kremenchutzky, M. Mult. Scler. (2009) [Pubmed]
  5. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. O'Connor, P. Expert. Opin. Biol. Ther (2007) [Pubmed]
  6. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. O'Connor, P.W., Li, D., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C., Paty, D.W., Stewart, J.A., Scheyer, R. Neurology (2006) [Pubmed]
  7. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. O'Connor, P., Miller, D., Riester, K., Yang, M., Panzara, M., Dalton, C., Miszkiel, K., Khan, O., Rice, G., Sheremata, W. Mult. Scler. (2005) [Pubmed]
  8. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. O'Connor, P.W., Goodman, A., Willmer-Hulme, A.J., Libonati, M.A., Metz, L., Murray, R.S., Sheremata, W.A., Vollmer, T.L., Stone, L.A. Neurology (2004) [Pubmed]
  9. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. O'Connor, P. Clin. Ther (2003) [Pubmed]
  10. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. O'Connor, P. Neurology (2002) [Pubmed]
 
WikiGenes - Universities